Allergy Therapeutics plc (LON:AGY – Get Free Report) shares traded down 5.4% on Wednesday . The stock traded as low as GBX 6.17 and last traded at GBX 7. Approximately 567,492 shares were traded during trading, an increase of 110% from the average session volume of 270,451 shares. The stock had previously closed at GBX 7.40.
Allergy Therapeutics Stock Performance
The firm’s 50 day simple moving average is GBX 8.13 and its 200-day simple moving average is GBX 9.97. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The company has a market cap of £436.94 million, a price-to-earnings ratio of -7.11, a PEG ratio of -30.70 and a beta of 0.87.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- Palantir’s Wild Ride: Inside the Stock Wall Street Can’t Agree On
- Has Broadcom Become Too Expensive for Its AI Story?
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
